MedPath

The experience of rucaparib in women with ovarian cancer

Not Applicable
Conditions
Ovarian cancer
Cancer
Malignant neoplasm of ovary
Registration Number
ISRCTN10125751
Lead Sponsor
HS Greater Glasgow and Clyde
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Stopped
Sex
Female
Target Recruitment
34
Inclusion Criteria

1. Women where a decision has been made to start rucaparib as part of standard care for maintenance treatment recurrent ovarian cancer following to platinum based chemotherapy and they have not yet started treatment
2. Written informed consent
3. Ability and willingness to complete questionnaires in English
4. Meet institutional criteria for treatment in standard practice

Exclusion Criteria

1. Prior treatment with a poly ADP ribose polymerase (PARP) inhibitor
2. Current treatment with another maintenance therapy for ovarian cancer
3. Participation in another trial of an investigational medicinal product (IMP) (participation in another observational or sample collection trial may be possible if both Sponsors agree and the burden on the patient is acceptable)

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath